From Wilsons research
Acrux unlikely to relicense AXIRON. Acrux does not ‘inherit’ the AXIRON NDA, which remains the property of Eli Lilly (and will also be withdrawn). We understand that maintaining the AXIRON patent appeal is inexpensive for Acrux. If Acrux’s patent rights are vindicated the potential damages claim could be material – at least 10 years of patent term was lost for a product which generated ~US$160m in annualised net sales.
Add to My Watchlist
What is My Watchlist?
